Tufts University Secures Spot Among Top 100 U.S. Patent Producers For 2025 Following Surge In Faculty Innovation

Tufts University secures 62nd place in the 2025 NAI Top 100 rankings for utility patents, highlighting breakthroughs in robotics, medicine, and 6G tech.

By: AXL Media

Published: Mar 21, 2026, 7:50 AM EDT

Source: Information for this report was sourced from Tufts University

Advancing To The Forefront Of National Innovation

Tufts University has achieved a significant milestone in its research trajectory, securing a position in the National Academy of Inventors’ Top 100 list for 2025. Ranking 62nd among U.S. universities, the institution has been recognized for its high volume of utility patents, which represent scientific breakthroughs with the potential for direct societal and commercial impact. Bernard Arulanandam, the vice provost for research, noted that the awards span a diverse array of disciplines, highlighting the vitality of a research enterprise focused on creating tangible products to improve human health and global infrastructure.

Biological Engineering And Living Machines

Among the most high-profile patents awarded to the School of Arts and Sciences is the development of "xenobots," led by professors Douglas Blackiston, Michael Levin, and Kelly McLaughlin. These tiny, programmable biological machines are constructed from frog cells and are capable of navigating aqueous environments, repairing damage, and moving collectively to perform tasks. By engineering these constructs to carry molecular payloads or sense environmental changes, the team has created a versatile platform with applications ranging from targeted drug delivery and biosensing to environmental remediation.

Breakthroughs In Medical And Dental Therapeutics

The School of Dental Medicine has contributed significantly to the university’s patent portfolio through the work of Jinkun Chen and Qisheng Tu. Their invention, AdipoAI, consists of small-molecule agonists designed to activate adiponectin receptors. This technology aims to treat chronic inflammation and diabetes-related bone diseases, which have historically been difficult to manage. Similarly, at the School of Medicine, Professor Peter Bullock secured a patent for engineered anti-PD-1 polypeptides. These proteins are designed to bind immune-checkpoint receptors with high specificity, offering a more precise tool for cancer immunotherapy and the treatment of autoimmune disorders.